

24. (Amended) A method of preventing or controlling after-cataract formation in the eye of a mammalian subject following lens implant surgery which comprises the step of implanting in the eye of the subject a lens coated with one or more TGF β inhibitors.

38. (Amended) The method according to claim 35 wherein the proteoglycan inhibitors of TGF β are selected from decorin, heparan sulfate proteoglycans and biglycan.

REMARKS

Claims 14 to 38 are pending, with claims 29 to 33 withdrawn from consideration. The Examiner has allowed claims 24 to 28, but has rejected claims 14 to 23 and 34 to 38 as being anticipated by WO 91/04748. Claims 14, 24 and 38 have been amended to correct typographical errors.

Claims 19 to 23

Claims 19 to 23 define an ophthalmological formulation comprising one or more inhibitors of TGF in an ophthalmologically acceptable carrier but excluding conventional pharmaceutically acceptable carriers. The claims expressly exclude from the claims formulations containing an inhibitor of TGF β in a conventional pharmaceutically acceptable carrier.